KR20230042744A - 항-코넥신 항체 제제 - Google Patents
항-코넥신 항체 제제 Download PDFInfo
- Publication number
- KR20230042744A KR20230042744A KR1020237006832A KR20237006832A KR20230042744A KR 20230042744 A KR20230042744 A KR 20230042744A KR 1020237006832 A KR1020237006832 A KR 1020237006832A KR 20237006832 A KR20237006832 A KR 20237006832A KR 20230042744 A KR20230042744 A KR 20230042744A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- val
- thr
- pro
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059502P | 2020-07-31 | 2020-07-31 | |
| US63/059,502 | 2020-07-31 | ||
| PCT/US2021/044043 WO2022026914A1 (en) | 2020-07-31 | 2021-07-30 | Anti-connexin antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230042744A true KR20230042744A (ko) | 2023-03-29 |
Family
ID=80002768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237006832A Pending KR20230042744A (ko) | 2020-07-31 | 2021-07-30 | 항-코넥신 항체 제제 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11912764B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4188544A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537316A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230042744A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234576A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021316119A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190474A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300245A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022026914A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116854816A (zh) * | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| IL300245A (en) | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| US20250277017A1 (en) * | 2022-04-29 | 2025-09-04 | Board Of Regents, The University Of Texas System | Compositions and methods for treating eye diseases |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
| EP4761813A1 (en) * | 2023-08-14 | 2026-06-24 | Alamab Therapeutics, Inc. | Method of treating stroke |
| WO2025245485A1 (en) * | 2024-05-24 | 2025-11-27 | Alamab Therapeutics, Inc. | Method of treating bone cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573131B (zh) | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| WO2009148613A1 (en) | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| US8956868B2 (en) | 2010-12-27 | 2015-02-17 | Lsip, Llc | Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor |
| WO2015027120A1 (en) | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| WO2016029191A2 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
| BR112018017031A2 (pt) * | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| AU2017224122B2 (en) * | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
| WO2017190152A1 (en) | 2016-04-29 | 2017-11-02 | Ocunexus Therapeutics, Inc. | Sustained release drug delivery devices |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| TWI911431B (zh) * | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MA49960A (fr) * | 2017-08-25 | 2021-06-02 | Omeros Corp | Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique |
| CN116854816A (zh) * | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| MX2021005708A (es) * | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| CA3156812A1 (en) * | 2019-10-02 | 2021-04-08 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| IL300245A (en) | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
-
2021
- 2021-07-30 IL IL300245A patent/IL300245A/en unknown
- 2021-07-30 CN CN202180062049.8A patent/CN116234576A/zh active Pending
- 2021-07-30 AU AU2021316119A patent/AU2021316119A1/en active Pending
- 2021-07-30 CA CA3190474A patent/CA3190474A1/en active Pending
- 2021-07-30 WO PCT/US2021/044043 patent/WO2022026914A1/en not_active Ceased
- 2021-07-30 EP EP21851080.8A patent/EP4188544A4/en active Pending
- 2021-07-30 KR KR1020237006832A patent/KR20230042744A/ko active Pending
- 2021-07-30 JP JP2023506315A patent/JP2023537316A/ja active Pending
- 2021-07-30 US US17/390,635 patent/US11912764B2/en active Active
-
2024
- 2024-01-17 US US18/415,511 patent/US20240309085A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021316119A1 (en) | 2023-03-02 |
| CA3190474A1 (en) | 2022-02-03 |
| US20240309085A1 (en) | 2024-09-19 |
| EP4188544A4 (en) | 2024-09-11 |
| US20220033492A1 (en) | 2022-02-03 |
| US11912764B2 (en) | 2024-02-27 |
| WO2022026914A1 (en) | 2022-02-03 |
| EP4188544A1 (en) | 2023-06-07 |
| JP2023537316A (ja) | 2023-08-31 |
| IL300245A (en) | 2023-03-01 |
| CN116234576A (zh) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912764B2 (en) | Anti-connexin antibody formulations | |
| KR102109053B1 (ko) | 안정한 수성 항체 제제 | |
| AU2013255413C1 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| EP3506886B1 (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| JP2020518587A (ja) | 抗lag3抗体の製剤および抗lag3抗体と抗pd−1抗体との共製剤 | |
| US20260049132A1 (en) | Anti-connexin antibody formulations | |
| TWI764097B (zh) | 包含抗cd47抗體的製劑及其製備方法和用途 | |
| MX2014013434A (es) | Formulaciones liofilizadas y acuosas de anticuerpo anti-cd40. | |
| WO2024240224A1 (zh) | 包含抗ccr8抗体的制剂及其用途 | |
| EP4094777A1 (en) | Recombinant fully human anti-tigit monoclonal antibody preparations, preparation method therefor and use thereof | |
| KR20210096105A (ko) | 항pcsk9 항체를 함유한 안정화 제제 | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| EP4548931A1 (en) | Anti-pcsk9 antibody preparation and use thereof | |
| HK40077586A (en) | Anto-connexin antibody formulations | |
| HK40061789B (en) | Stable, aqueous antibody formulations | |
| HK40096813A (en) | Anti-pcsk9 antibody preparation and use thereof | |
| HK40061789A (en) | Stable, aqueous antibody formulations | |
| CN121490076A (zh) | 一种稳定的抗人masp2单克隆抗体制剂 | |
| CN117643628A (zh) | 新型冠状病毒中和抗体药物组合物及其用途 | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |